NASDAQ · Biotechnology · USD
Biomea Fusion, Inc. (BMEA) Stock Analysis
Biomea Fusion, Inc. (BMEA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
BMEA Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.74
- Previous Close
- $0.74
- Day's Range
- 0.68–0.75
- 52-Week Range
- 0.80–2.24
- Volume
- 3.03M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- −0.30
Valuation
- Market Cap
- $60.47M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.19
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$61.80M
- Shares Outstanding
- 72.30M
- 1-Year Return
- −56.60%
Dividend and dates
- Earnings Date
- November 3, 2026estimated
- Avg Volume
- 1.84M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, BMEA closed at $0.69, −56.60% over 1 year.
Biomea Fusion, Inc. (BMEA) has a market capitalization of $60.47M.
In fiscal 2025, BMEA reported revenue of $0.00.
BMEA Stock Return by Calendar Year
Biomea Fusion, Inc. (BMEA) return since Apr 2021: what $10,000 became
- 1 year
- $10,000 $4,340
- −56.60%
- 5 years
- $10,000 $622
- −93.78%
- Since Apr 2021
- $10,000 $371
- −96.29%
If you had invested $10,000 in Biomea Fusion, Inc. (BMEA) at the close on April 16, 2021, the earliest close on record here, it would have been worth $371 at the close on October 21, 2026: −96.29% in total, −44.98% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −44.35% |
| 2025 | −68.04% |
| 2024 | −73.28% |
| 2023 | +72.24% |
| 2022 | +13.15% |
| 2021 (partial year) | −59.95% |
As of October 21, 2026.
BMEA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$61.80M | — |
| 2024 | $0.00 | −$138.43M | — |
| 2023 | $0.00 | −$117.26M | — |
| 2022 | $0.00 | −$81.83M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$81.31M | −$61.80M | — |
| 2024 | $0.00 | — | −$144.07M | −$138.43M | — |
| 2023 | $0.00 | — | −$126.14M | −$117.26M | — |
| 2022 | $0.00 | — | −$83.63M | −$81.83M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Citizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price Target
BenzingaHC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $4 Price Target
BenzingaWhat’s Going On With Biomea Fusion (BMEA) Stock After Hours?
BenzingaBiomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
MarketBeatBiomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss - Slideshow
SeekingAlphaBiomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript
SeekingAlpha
All 20 articles ↓Show fewer ↑
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
YahooBiomea Fusion BMF-650 Phase 1 Weight Loss Results Remain Preliminary, With Longer-Term Trials And Toxicology Studies Still Outstanding
BenzingaBiomea Fusion Reports Phase 1 Results For Oral GLP-1 Candidate BMF-650, Showing Consistent Weight Reduction And Encouraging Tolerability
BenzingaBiomea Fusion Stock Climbs 7% After-Hours: What's Going On?
BenzingaBiomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
YahooBiomea Fusion To Report Results From Phase I GLP-131 Clinical Study Evaluating BMF-650, Investigational Next-Gen Oral Small-Molecule GLP-1 Receptor Agonist, On October 13
BenzingaBrookline Capital Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $10
BenzingaBiomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway Pressure
SeekingAlphaBearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data
BenzingaBiomea Fusion Announces Termination of Proposed Public Offering of Securities
YahooBiomea Fusion Terminates Proposed Public Offering Of Securities Due To Market Conditions
BenzingaBiomea Fusion Shares Fall 19% After Hours: Here’s Why
BenzingaBiomea Fusion Announces Proposed Public Offering of Securities
YahooBiomea Fusion Says Topline Data From Phase 1 Obesity Trial Of BMF-650 Now Expected In October, Pushed From Q3
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B